Working in collaboration with GSK, the aim of this project is to develop cutting-edge sensors capable of detecting precise structural changes, such as high-order structures and base mismatches, that are critical in drug development and quality control.  Previous work in the research group has demonstrated that surface-enhanced Raman scattering (SERS) can be used to detect minor structural changes in oligonucleotide sequences. These minute changes can significantly impact the function and efficacy of oligonucleotide-based drugs. The high-resolution spectra obtained from SERS can differentiate between closely related molecular structures, making it an invaluable tool for quality control in the pharmaceutical industry, ensuring that the final product is consistent and free of undesired modifications.

SERS sensors are also advantageous for the real-time monitoring of molecular interactions. This feature is particularly beneficial in studying oligonucleotide interactions in various environments, such as different pH levels, ionic strengths, and temperatures. By continuously monitoring these interactions, SERS can provide insights into the stability and dynamics of oligonucleotide structures under physiological conditions. This real-time data is crucial for understanding how environmental factors influence the efficacy and stability of therapeutic oligonucleotides, guiding the design of more stable and effective drug formulations. Furthermore, the ability to perform in situ monitoring without extensive sample preparation makes SERS an attractive option for clinical diagnostics and personalized medicine, where rapid and accurate analysis is essential.

Currently, there are no SERS-based sensors specifically tailored for the pharmaceutical industry to monitor drug development processes, particularly for oligonucleotide-based therapies. This project aims to fill this gap by developing SERS-based sensors for detecting high-order structures, single base mismatches, and other critical modifications with high sensitivity.  Methods developed in this project will be applied to real-world pharmaceutical samples to assess whether the methods can be used to enhance quality assurance processes and accelerate the development of safe and effective oligonucleotide-based drugs. 

The project will include an industrial placement at GSK and continual engagement with industrial supervisors throughout the project.